Screening of cytokines to enhance vaccine effects of heat shock protein 70-rich tumor cell lysate

Journal of Bioscience and Bioengineering

Volumn 100, Issue 1, 2005, Pages 36-42

  Ito, Akira ^a   Fujioka, Masatake ^a   Tanaka, Kouji ^a   Kobayashi, Takeshi ^a,b   Honda, Hiroyuki ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b CHUBU UNIVERSITY   (Japan)

Author keywords

Cancer immunotherapy; Cancer vaccine; Heat shock protein; Interleukin 12; Melanoma

Indexed keywords

DRUG THERAPY; IMMUNOLOGY; PROTEINS; SCREENING; TUMORS; VACCINES;

CANCER IMMUNOTHERAPY; CANCER VACCINE; HEAT SHOCK PROTEINS; INTERLEUKIN-12; MELANOMA;

CYTOLOGY;

BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; HEAT TREATED CELL LYSATE VACCINE; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; RECOMBINANT CYTOKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LYSATE; CONTROLLED STUDY; DRUG EFFICACY; FREEZE THAWING; HEAT TREATMENT; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SCREENING; TUMOR CELL;

EID: 27644582468     PISSN: 13891723     EISSN: None     Source Type: Journal    
DOI: 10.1263/jbb.100.36     Document Type: Article

References (36)

1. Mocellin, S., Mandruzzato, S., Bronte, V., Lise, M., and Nitti, D.: Part I: vaccines for solid tumours. Lancet Oncol., 5, 681-689 (2004).
2. Schlesinger, M. J.: Heat shock proteins. J. Biol. Chem., 265, 12111-12114 (1990).
3. Ménoret, A. and Chandawarkar, R.: Heat-shock protein-based anticancer immunotherapy: an idea whose time has come. Semin. Immunol., 25, 654-660 (1998).
4. Srivastava, P. K., Menoret, A., Basu, S., Binder, R. J., and McQuade, K. L.: Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity, 8, 657-665 (1998).
5. Tamura, Y., Peng, P., Liu, K., Daou, M., and Srivastava, P. K.: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science, 278, 117-120 (1997).
6. Udono, H. and Srivastava, P. K.: Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med., 178, 1391-1396 (1993).
7. Peng, P., Menoret, A., and Srivastava, P. K.: Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography. J. Immunol. Methods, 204, 13-21 (1997).
8. Asea, A., Kraeft, S. K., Kurt-Jones, E. A., Stevenson, M. A., Chen, L. B., Finberg, R. W., Koo, G. C., and Calderwood, S. K.: HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperon and cytokine. Nat. Med., 6, 435-442 (2000).
9. Mise, K., Kan, N., Okino, T., Nakanishi, M., Satoh, K., Teranuma, Y., Yamasaki, S., Ohgaki, K., and Tobe, T.: Effect of heat treatment on tumor cells and antitumor effector cells. Cancer Res., 50, 6199-6202 (1990).
10. Mondovi, B., Santoro, A. S., Strom, R., Faiola, R., and Fanelli, A. R.: Increased immunogenicity of Ehrlich ascites cells after heat treatment. Cancer, 30, 885-888 (1972).
11. Ozdemirli, M., Akdeniz, H., el-Khatib, M., and Ju, S. T.: A novel cytotoxicity of CD4+ Th1 clones on heat-shocked tumor targets. I. Implications for internal disintegration model for target death and hyperthermia treatment of cancers. J. Immunol., 147, 4027-4034 (1991).
12. Ito, A., Shinkai, M., Honda, H., Wakabayashi, T., Yoshida, J., and Kobayashi, T.: Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol. Immunother., 50, 515-522 (2001).
13. Ito, A., Shinkai, M., Honda, H., Yoshikawa, K., Saga, S., Wakabayashi, T., Yoshida, J., and Kobayashi, T.: Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol. Immunother., 52, 80-88 (2003).
14. Graner, M. W., Zeng, Y., Feng, H., and Katsanis, E.: Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol. Immunother., 52, 226-234 (2003).
15. Melcher, A., Todryk, S., Hardwick, N., Ford, M., Jacobson, M., and Vile, G.: Tumor immunogenicity is determined by mechanism of cell death via induction of heat shock protein expression. Nat. Med., 4, 581-587 (1998).
16. Todryk, S. M., Eaton, J., Birchall, L., Greenhalgh, R., Soars, D., Dalgleish, A. G., Melcher, A. A., and Pandha, H. S.: Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity. Cancer Immunol. Immunother., 53, 323-330 (2004).
17. Wells, A. D., Rai, S. K., Salvato, M. S., Band, H., and Malkovsky, M.: Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. Int. Immunol., 10, 609-617 (1998).
18. Ito, A., Shinkai, M., Bouhon, I. A., Honda, H., and Kobayashi, T.: Induction of TNF-α gene expression by heat inducible promoter gadd 153. Jpn. J. Hyperthermic Oncol., 16, 91-98 (2000).
19. Ito, A., Matsuoka, F., Honda, H., and Kobayashi, T.: Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Immunol. Immunother., 53, 26-32 (2003).
20. Ward, S., Casey, D., Labarthe, M. C., Whelan, M., Dalgleish, A., Pandha, H., and Todryk, S.: Immunotherapeutic potential of whole tumour cells. Cancer Immunol. Immunother., 51, 351-357 (2002).
21. Ye, J., Chen, G. S., Song, H. P., Li, Z. S., Huang, Y. Y., Qu, P., Sun, Y. J., Zhang, X. M., and Sui, Y. F.: Heat shock protein 70/MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific cellular immune responses in vivo. Cancer Immunol. Immunother., 53, 825-834 (2004).
22. Ito, A., Tanaka, K., Kondo, K., Shinkai, M., Honda, H., Matsumoto, K., Saida, T., and Kobayashi, T.: Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Sci., 94, 308-313 (2003).
23. Basu, S., Binder, R. J., Suto, R., Andersen, K. M., and Srivastava, P. K.: Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol., 12, 1539-1546 (2000).
24. Fuchs, E. J. and Matzinger, P.: Is cancer dangerous to the immune system? Semin. Immunol., 8, 271-280 (1996).
25. Matzinger, P.: Tolerance, danger, and the extended family. Annu. Rev. Immunol., 12, 991-1045 (1994).
26. Todryk, S., Melcher, A. A., Hardwick, N., Linardakis, E., Bateman, A., Colombo, M. P., Stoppacciaro, A., and Vile, R. G.: Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J. Immunol., 163, 1398-1408 (1999).
27. Basu, S., Binder, R. J., Ramalingam, T., and Srivastava, P. K.: CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity, 14, 303-313 (2001).
28. Becker, T., Hartl, F. U., and Wieland, F.: CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J. Cell Biol., 158, 1277-1285 (2002).
29. Asea, A., Rehli, M., Kabingu, E., Boch, J. A., Bare, O., Auron, P. E., Stevenson, M. A., and Calderwood, S. K.: Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J. Biol. Chem., 277, 15028-15034 (2002).
30. Srivastava, P. K., Udono, H., Blachere, N. E., and Li, Z.: Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics, 39, 93-98 (1994).
31. Steinman, R. M.: The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 9, 271-296 (1991).
32. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90, 3539-3543 (1993).
33. Rosenberg, S. A., Grimm, E. A., McGrogan, M., Doyle, M., Kawasaki, E., Koths, K., and Mark, D. F.: Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science, 223, 1412-1414 (1984).
34. Lee, P., Wang, F., Kuniyoshi, J., Rubio, V., Stuges, T., Groshen, S., Gee, C., Lau, R., Jeffery, G., Margolin, K., Marty, V., and Weber, J.: Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol, 19, 3836-3847 (2001).
35. Rodolfo, M. and Colombo, M. P.: Interleukin-12 as an adjuvant for cancer immunotherapy. Methods, 19, 114-120 (1999).
36. Portielje, J. E., Kruit, W. H., Eerenberg, A. J., Schuler, M., Sparreboom, A., Lamers, C. H., Gratama, J. W., Stoter, G., Huber, C., and Hack, C. E.: Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant. Cancer Immunol. Immunother., 54, 37-43 (2005).